Kraig Biocraft Laboratories, Inc.

Pre-commercial recombinant spider-silk developer with a going-concern paragraph, net capital deficiency and a current ratio near 0.18.

Strengths

• Claims technology leadership in scalable recombinant spider silk with Vietnam production base
• $10M standby equity facility provides a financing avenue

Risks

• Going concern and net capital deficiency; current/quick ratio ~0.18 (8th–9th pct)
• ROA -1.4; positive ROE (87.6th pct) is a negative-equity artifact, not real profitability
• ~4 quarters runway and reliance on dilutive SEPA share sales

Notable findings

• Going concern15 The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2024, and as of December 31, 2025, include an explanatory paragraph stating that our ne
• Cash burnNegative free cash flow (-1.8M)
• Weak liquidityCurrent ratio 0.18 (<1)